New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2013
10:09 EDTUNM, NVS, IBM, COST, N, VZ, SRC, MIDD, HMC, ALU, LVS, WLT, KEY, STR, KBH, DHI, D, ANROn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Alcatel-Lucent (ALU) upgraded to Neutral from Sell at Citigroup... Costco (COST) upgraded to Market Perform from Underperform at Bernstein... D.R. Horton (DHI) upgraded to Market Perform from Underperform at Raymond James... Honda (HMC) upgraded to Outperform from Neutral at Macquarie... IBM (IBM) upgraded to Hold from Sell at Societe Generale... KB Home (KBH) upgraded to Market Perform from Underperform at Raymond James... Middleby (MIDD) upgraded to Outperform from Neutral at RW Baird.. Novartis (NVS) upgraded to Buy from Neutral at Citigroup... Platinum Group (PLG) upgraded to Outperform from Sector Perform at RBC Capital... Questar (STR) upgraded to Buy from Neutral at Citigroup... Spirit Realty (SRC) upgraded to Outperform from Market Perform at Raymond James... Unum Group (UNM) upgraded to Overweight from Equal Weight at Barclays... Verizon (VZ) upgraded to Buy from Hold at Canaccord... KeyCorp (KEY) upgraded to Outperform from Sell at CLSA... Alpha Natural (ANR) upgraded to Buy from Hold at Dahlman Rose... Walter Energy (WLT) upgraded to Buy from Hold at Dahlman Rose... NetSuite (N) upgraded to Buy from Neutral at Lazard Capital... Disney (D) upgraded to Buy from Neutral at B. Riley Caris... Las Vegas Sands (LVS) upgraded to Neutral from Sell at Compass Point.
News For ALU;COST;DHI;HMC;IBM;KBH;MIDD;NVS;STR;SRC;UNM;KEY;VZ;ANR;WLT;N;D;LVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
December 9, 2014
10:17 EDTVZVerizon CFO Shammo says sees promotional pricing 'settling down' in 2015
Says Q4 has been a "pretty exciting" period, says seeing increase in activations, but seeing some increase in churn as well. Says has seen high volume in Q4 sales. Says continues to see strong momentum for wireless customer growth in Q4. Sees promotional pricing "settling down" in 2015. Shammo says social media, press has built this up as a price war; says rival's half-priced promotion "not as dramatic" as it looks. Says tablets a "tremendous" growth area for industry. Says streaming TV to mobile to begin in mid-2015. Says that over time, company believes can increase margins. Comments made at the UBS Global Media & Communications Conference. Verizon shares are down 3.8% to $47.04 in morning trading.
09:38 EDTVZActive equity options trading
Subscribe for More Information
07:40 EDTVZVerizon competition increased, company should be able to respond, says Canaccord
Subscribe for More Information
07:32 EDTVZUBS to hold a conference
Subscribe for More Information
07:29 EDTCOSTCostco December weekly volatility increases into Q1 and outlook
Costco December weekly call option implied volatility is at 32, December is at 16, January is at 15, April is at 14; compared to its 26-week average of 16 according to Track Data suggesting larger near term price movement into the expected release of Q1 results on December 10.
06:43 EDTKEYKeyCorp initiated with a Buy at Guggenheim
Subscribe for More Information
06:15 EDTVZVerizon downgraded at RW Baird
As previously reported, Baird downgraded Verizon to Neutral from Outperform. The firm downgraded shares citing last night's negative pre-announcement due to increasing competitive concerns, margin pressures, higher churn, and full valuation. Price target lowered to $50 from $54.
06:01 EDTVZVerizon downgraded to Neutral from Outperform at RW Baird
Subscribe for More Information
December 8, 2014
18:31 EDTHMCHonda to expand air bag recall worldwide, Nikkei reports
Subscribe for More Information
18:24 EDTVZOn The Fly: After Hours Movers
Subscribe for More Information
17:05 EDTVZVerizon sees Q4 impacts of promotional offers will pressure wireless EBITDA, EPS
Subscribe for More Information
13:07 EDTNVSNovartis announces data from Jakavi trial
Novartis (NVS) announced data from the largest clinical trial of myelofibrosis patients treated with Jakavi, supporting the safety profile and efficacy benefit as measured in primary and secondary endpoints respectively. In an analysis of 1,144 patients treated with Jakavi to date in this ongoing expanded access study, 69% of patients achieved >50% reduction in spleen size from baseline and patients also experienced a clinically meaningful improvement in myelofibrosis symptom score, important treatment goals for patients with myelofibrosis. Findings from the study were presented at the 56th Annual Meeting of the American Society of Hematology in San Francisco, California. Novartis research and development efforts, in collaboration with Incyte Corporation (INCY), include early-phase and post-marketing studies in myelofibrosis and other myeloproliferative neoplasms. More than 50 abstracts on ruxolitinib are being presented at ASH, including three oral presentations exploring combinations of ruxolitinib with various investigational compounds, evaluating the possibility of simultaneously targeting multiple cancer pathways that may be involved in the pathogenesis of myelofibrosis. The JUMP study is a Phase IIIb, expanded-access trial for countries with no access to Jakavi outside of a clinical trial. The open-label, multicenter study analyzed 1,144 enrolled myelofibrosis patients who received daily starting doses of either 5 mg, 15 mg or 20 mg of Jakavi twice daily based on platelet counts at baseline. The primary endpoint is assessment of safety and tolerability of Jakavi. Overall, the safety and efficacy profile of Jakavi was consistent with previous studies.
13:05 EDTNVSNovartis reports six-year results from Phase III ENESTnd study
Subscribe for More Information
11:30 EDTNVSLeerink generics pharmaceutical analyst holds analyst/industry conference call
Subscribe for More Information
11:10 EDTHMCVolkswagen sees challenging developments continuing for rest of year
Volkswagen (VLKAY) said, “The challenging developments on markets worldwide – above all in Eastern Europe and South America – will continue for the remainder of this year. The Volkswagen Passenger Cars brand handled these challenges successfully during the course of the year, but was not entirely immune to their impact.” Other publicly traded companies in the passenger automotive space include Fiat Chrysler (FCAU), Ford (F), General Motors (GM), Honda (HMC), Nissan (NSANY), and Toyota (TM).
10:00 EDTDOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:02 EDTANRAlpha Natural announces WARN notices for eight W. Virginia coal mines expire
Subscribe for More Information
06:27 EDTDDominion initiated with a Market Perform at Wells Fargo
Subscribe for More Information
06:15 EDTWLTWalter Energy implied volatility of 188 at upper end of index mean range
Subscribe for More Information
05:42 EDTNVSSandoz Phase III data shows filgrastim has similar safety, efficacy as NEUPOGEN
Sandoz, a Novartis (NVS) company, announced Phase III data that demonstrated similarity of its investigational biosimilar filgrastim compared to the US-licensed reference product, Amgen's (AMGN) NEUPOGEN in the prevention of severe neutropenia in patients with breast cancer receiving neoadjuvant myelosuppressive chemotherapy. The study also showed that repeated switching at each cycle between the investigational biosimilar and the originator filgrastim showed no impact on efficacy, safety or immunogenicity. The PIONEER study was a Phase III study designed to compare the efficacy and safety of the investigational biosimilar and the reference product with respect to mean duration of severe neutropenia following Cycle 1 chemotherapy. PIONEER was a randomized, double-blind, four-group, multi-center non-inferiority trial conducted at 27 centers. The trial randomized 218 breast cancer patients receiving neoadjuvant myelosuppressive chemotherapy.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use